PI3K activation is associated with intracellular sodium/iodide symporter protein expression in breast cancer
Open Access
- 25 July 2007
- journal article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 7 (1), 137-10
- https://doi.org/10.1186/1471-2407-7-137
Abstract
The sodium/iodide symporter (NIS) is a membrane glycoprotein mediating active iodide uptake in the thyroid gland and is the molecular basis for radioiodide imaging and therapeutic ablation of thyroid carcinomas. NIS is expressed in the lactating mammary gland and in many human breast tumors, raising interest in similar use for diagnosis and treatment. However, few human breast tumors have clinically evident iodide uptake ability. We previously identified PI3K signaling as important in NIS upregulation in transgenic mouse models of breast cancer, and the PI3K pathway is commonly activated in human breast cancer. NIS expression, subcellular localization, and function were analyzed in MCF-7 human breast cancer cells and MCF-7 cells stably or transiently expressing PI3K p110alpha subunit using Western blot of whole cell lysate, cell surface biotinylation Western blot and immunofluorescence, and radioiodide uptake assay, respectively. NIS localization was determined in a human breast cancer tissue microarray using immunohistochemical staining (IHC) and was correlated with pre-existing pAkt IHC data. Statistical analysis consisted of Student's t-test (in vitro studies) or Fisher's Exact Test (in vivo correlational studies). In this study, we demonstrate that PI3K activation in MCF-7 human mammary carcinoma cells leads to expression of underglycosylated NIS lacking cell surface trafficking necessary for iodide uptake ability. PI3K activation also appears to interfere with cell surface trafficking of exogenous NIS as well as all-trans retinoic acid-induced endogenous NIS. A correlation between NIS expression and upregulation of PI3K signaling was found in a human breast cancer tissue microarray. Thus, the PI3K pathway likely plays a major role in the discordance between NIS expression and iodide uptake in breast cancer patients. Further study is warranted to realize the application of NIS-mediated radioiodide ablation in breast cancer.Keywords
This publication has 23 references indexed in Scilit:
- Hydrocortisone and Purinergic Signaling Stimulate Sodium/Iodide Symporter (NIS)-Mediated Iodide Transport in Breast Cancer CellsMolecular Endocrinology, 2006
- PIK3CA mutations in breast cancer are associated with poor outcomeBreast Cancer Research and Treatment, 2005
- Cell Surface Targeting Accounts for the Difference in Iodide Uptake Activity between Human Na+/I−Symporter and Rat Na+/I−SymporterJournal of Clinical Endocrinology & Metabolism, 2005
- The N‐terminus of phosphoinositide 3‐kinase‐C2β regulates lipid kinase activity and binding to clathrinJournal of Cellular Physiology, 2005
- Inhibition of Heat Shock Protein 90, a Novel RET/PTC1-associated Protein, Increases Radioiodide Accumulation in Thyroid CellsPublished by Elsevier BV ,2004
- The Na+/I− Symporter Mediates Iodide Uptake in Breast Cancer Metastases and Can Be Selectively Down-Regulated in the ThyroidClinical Cancer Research, 2004
- Hormonal Regulation of Radioiodide Uptake Activity and Na+/I- Symporter Expression in Mammary GlandsJournal of Clinical Endocrinology & Metabolism, 2000
- Retinoic acid induces sodium/iodide symporter gene expression and radioiodide uptake in the MCF-7 breast cancer cell lineProceedings of the National Academy of Sciences of the United States of America, 2000
- An Immunohistochemical Study of Na+/I- Symporter in Human Thyroid Tissues and Salivary Gland TissuesEndocrinology, 1998
- N-linked Glycosylation of the Thyroid Na+/I− Symporter (NIS)Journal of Biological Chemistry, 1998